Antev

Antev is a Phase III-ready biotech focused on developing Teverelix, a GnRH antagonist, for specific, high-risk patient populations in prostate cancer and acute urinary retention. The company has a lean, experienced leadership team with deep expertise in clinical development and CMC, positioning it to advance its registration-ready data package. Its strategy targets clear medical needs in men's health where current treatments pose significant cardiovascular risks, aiming for a differentiated market entry.

Small molecule GnRH antagonist (Teverelix) designed for rapid hormone suppression without the initial testosterone flare associated with agonists.

In prostate cancer, Antev faces competition from established GnRH agonists (e.g., leuprolide) and newer antagonists (e.g., degarelix, oral relugolix). Its strategy is to differentiate on superior CV safety in a high-risk subpopulation. In AUR, it would compete against immediate surgical interventions, positioning itself as a first-line pharmacological alternative.